Currently, several A2AR antagonists (such as CPI-444, AZD4635, NIR178, and PBF-509) are being evaluated as single agent or in combination with anti-PD-1 mAb in clinical trials for treatment of cancer patients bearing solid tumors (Table 1). The gene discussed is ADORA2A; the disease is cancer.